Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965587 | 1.00 | SCN9A (0.33) | SCN9AKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL18983845 | 1.00 | SCN9A (0.33) | SCN9AKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL20973539 | 0.81 | SMN1; SMN2 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL17438862 | 0.81 | SMN1; SMN2 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL16972996 | 0.79 | EPHX1 (0.40) | SCN9AEPHX2 | |
| SCHEMBL18984269 | 0.79 | ALDH1A1 (0.35) | SCN9AKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL18984267 | 0.79 | ALDH1A1 (0.35) | SCN9AKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL15719047 | 0.79 | CHRNB2 (0.32) | — | |
| SCHEMBL27191329 | 0.79 | CHRNB2 (0.32) | — | |
| SCHEMBL27143501 | 0.79 | CHRNB2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | SCN9A 3426/4885KDM4E 1474/4885MEN1 3091/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | SCN9A 3426/4885KDM4E 1474/4885MEN1 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.